Opinion

Published within

« | ... | 1558 | 1559 | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

New personal care review: antibacterial silver finds new home in nail varnish

In this month's run-through of the latest launches from the personal care industry, an antibacterial silver ingredient is part of a novel formulation in the nail varnish category. In other news, a US company could court controversy with the launch of a lipstick for babies, while a soap product takes its cues from confectionery in a bid to enhance its indulgence appeal.

Published By Datamonitor
14 May 2012
Expert View
Expert View

New drinks review: QR branding sees wine embrace the smartphone era

The emergence of QR codes in line with growing consumer take-up of smartphone technology is offering diverse marketing and branding opportunities to consumer goods companies, as evidenced by the sparkling wine launch that headlines this month's rundown of drinks innovations. Meanwhile, new flavors are emerging in the gin segment and novel formats are being explored for liqueurs and bottled water.

Published By Datamonitor
14 May 2012
Expert View
Expert View

New household products review: bag-in-box laundry detergent tests the ecological waters

Aligning environmentally friendly packaging with an ecological product formula, one French manufacturer is hoping to stand out in the laundry detergent category, as reported in this month's summary of household goods innovations. Meanwhile, reed diffusers have been taken to a new, more decorative level, and fragrancing microcapsules have emerged in the floor cleaners segment.

Published By Datamonitor
14 May 2012
Expert View
Expert View

Arena Pharmaceuticals: positive vote for Lorqess, but will commercial success follow?

Lorqess has moved one step closer to approval for the treatment of obesity following a positive review by the FDA advisory committee. The result came as a surprise to some, after the drug was rejected in 2010 due to safety concerns. Despite the good news for Arena Pharmaceuticals, the drug's commercial prospects remain uncertain: the path to launch is unclear, and uptake may be slow.

Published By Datamonitor
15 May 2012
Expert View
Expert View

Social media provides insurers with the opportunity to develop closer relationships with customers

The UK general insurance industry needs to connect with its customers and develop lasting relationships with them in order to improve retention and cross-selling opportunities. Social media can be utilized to enhance the provider-customer relationship, by increasing the number of touchpoints between the insurer and customers, and by building trust in the brand.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

Electricals manufacturers spark hope for the high street

Electricals retailer Dixons has revealed that its suppliers are offering traditional retailers improved terms compared to pureplay internet operations, in return for showcasing their products in-store. This is the latest in a series of events in which suppliers appear to have recognized the need to prioritize and protect the physical retail channel.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012

« | ... | 1558 | 1559 | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | ... | » »|

No help is available.